TY - JOUR
T1 - Use of vitamins and dietary supplements by patients with multiple sclerosis a review
AU - Evans, Emily
AU - Piccio, Laura
AU - Cross, Anne H.
N1 - Funding Information:
serving as a paid consultant for Teva and Genzyme/ Sanofi. Dr Piccio reported receiving research funding from Biogen and Alector. Dr Cross reported serving as a paid consultant for AbbVie, Bayer, Biogen, EMD-Serono, Genzyme/Sanofi, Genentech/ Roche, Mallinckrodt, Novartis, and Teva; and being funded in part by the Manny and Rosalyn Rosenthal–John L Trotter MS Center Chair in Neuroimmunology of Barnes-Jewish Hospital Foundation.
Publisher Copyright:
© 2018 American Medical Association. All rights reserved.
PY - 2018/8
Y1 - 2018/8
N2 - IMPORTANCE Surveys of patients with multiple sclerosis report that most are interested in modifying their diet and using supplements to potentially reduce the severity and symptoms of the disease. This review provides an updated overview of the current state of evidence for the role that vitamins and dietary supplements play in multiple sclerosis and its animal models, with an emphasis on recent studies, and addresses biological plausibility and safety issues. OBSERVATIONS Several vitamins and dietary supplements have been recently explored both in animal models and by patients with multiple sclerosis. Most human trials have been small or nonblinded, limiting their generalizability. Biotin and Vitamin D are currently being tested in large randomized clinical trials. Smaller trials are ongoing or planned for other supplements such as lipoic acid and probiotics. The results of these studiesmay help guide clinical recommendations. CONCLUSIONS AND RELEVANCE At the present time, the only vitamin with sufficient evidence to support routine supplementation for patients with multiple sclerosis is Vitamin D. Vitamin deficiencies should be avoided. It is important for clinicians to know which supplements their patients are taking and to educate patients on any known efficacy data, along with any potential medication interactions and adverse effects of individual supplements. Given that dietary supplements and vitamins are not subject to the same regulatory oversight as prescription pharmaceuticals in the United States, it is recommended that vitamins and supplements be purchased from reputable manufacturers with the United States Pharmacopeia designation.
AB - IMPORTANCE Surveys of patients with multiple sclerosis report that most are interested in modifying their diet and using supplements to potentially reduce the severity and symptoms of the disease. This review provides an updated overview of the current state of evidence for the role that vitamins and dietary supplements play in multiple sclerosis and its animal models, with an emphasis on recent studies, and addresses biological plausibility and safety issues. OBSERVATIONS Several vitamins and dietary supplements have been recently explored both in animal models and by patients with multiple sclerosis. Most human trials have been small or nonblinded, limiting their generalizability. Biotin and Vitamin D are currently being tested in large randomized clinical trials. Smaller trials are ongoing or planned for other supplements such as lipoic acid and probiotics. The results of these studiesmay help guide clinical recommendations. CONCLUSIONS AND RELEVANCE At the present time, the only vitamin with sufficient evidence to support routine supplementation for patients with multiple sclerosis is Vitamin D. Vitamin deficiencies should be avoided. It is important for clinicians to know which supplements their patients are taking and to educate patients on any known efficacy data, along with any potential medication interactions and adverse effects of individual supplements. Given that dietary supplements and vitamins are not subject to the same regulatory oversight as prescription pharmaceuticals in the United States, it is recommended that vitamins and supplements be purchased from reputable manufacturers with the United States Pharmacopeia designation.
UR - http://www.scopus.com/inward/record.url?scp=85055757724&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2018.0611
DO - 10.1001/jamaneurol.2018.0611
M3 - Review article
C2 - 29710293
AN - SCOPUS:85055757724
VL - 75
SP - 1013
EP - 1021
JO - JAMA Neurology
JF - JAMA Neurology
SN - 2168-6149
IS - 8
ER -